Avadel Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Avadel Pharmaceuticals generated cash of -$128,511,000, which is less than the previous year. Cash used in financing activities reached the amount of $135,335,000 last year. Net change in cash is therefore -$42,814,000.
Cash Flow
| 2014 | -10.61M | -43.08M | 95.99M |
|---|---|---|---|
| 2015 | 84.29M | -31.73M | -23.75M |
| 2016 | 18.90M | -36.63M | -7.95M |
| 2017 | 16.66M | -15.69M | -23.31M |
| 2018 | -82.71M | -36.98M | 112.65M |
| 2019 | -38.32M | 38.72M | -27K |
| 2020 | -48.73M | -69.72M | 179.68M |
| 2021 | -77.31M | 56.92M | 263K |
| 2022 | -70.30M | 79.69M | 14.54M |
| 2023 | -128.51M | -50.09M | 135.33M |
AVDL Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 73.98M | 50.70M | 71.72M | 9.77M | 9.32M | 16.56M | 39.21M | 65.06M | 39.76M | 6.63M |
Operating activities | ||||||||||
Net income | -160.27M | -137.46M | -77.32M | 7.02M | -33.22M | -95.30M | 67.25M | -41.27M | 40.65M | -84.90M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.76M | 1.49M | 815K | 1.69M | 2.48M | 7.43M | 4.88M | 14.48M | 13.13M | 14.14M |
Stock-based compensation expense | 15.81M | 7.01M | 8.87M | 2.99M | 519K | 0 | 8.07M | 14.67M | 7.74M | 2.69M |
| Deferred income tax benefit | 15.81M | 7.01M | 8.87M | 2.99M | 519K | 0 | 8.07M | 14.67M | 7.74M | 2.69M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -10.21M | 30K | 2.79M | 8.28M | 2.47M | 3.45M | 3.07M | -10.05M | -8.10M | 3.42M |
Inventories | -9.53M | -30K | -2.79M | -1.35M | 1.15M | 711K | -2.89M | 1.83M | 2.54M | -3.11M |
Accounts payable | 1.54M | -3.10M | 4.23M | -2.78M | 4.64M | -2.03M | 596K | -434K | -3.88M | 1.09M |
Cash generated by operating activities | -128.51M | -70.30M | -77.31M | -48.73M | -38.32M | -82.71M | 16.66M | 18.90M | 84.29M | -10.61M |
Investing activities | ||||||||||
Purchases Of Investments | -237.22M | -3.41M | -61.76M | -131.40M | -24.64M | -376.31M | -151.00M | -107.60M | -50.59M | -68.27M |
Investments In Property Plant And Equipment | 0 | -716K | -26K | -98K | -29K | -20.17M | -53.70M | -1.20M | -1.62M | -1.72M |
Acquisitions Net | 0 | -80.41M | 16.5M | 25.5M | 154K | 20M | 53.11M | 628K | 779K | 0 |
Cash generated by investing activities | -50.09M | 79.69M | 56.92M | -69.72M | 38.72M | -36.98M | -15.69M | -36.63M | -31.73M | -43.08M |
Financing activities | ||||||||||
Common Stock Issued | 146.06M | 25.31M | 263K | 179.68M | 118K | 0 | 404K | 440K | 6.99M | 132.26M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | -27.63M | -22.36M | 0 | 0 | 0 |
Repayments of term debt | -38.66M | 0 | 0 | 0 | 0 | -143.75M | 0 | -1.50M | -4.91M | -34.55M |
Cash used in financing activities | 135.33M | 14.54M | 263K | 179.68M | -27K | 112.65M | -23.31M | -7.95M | -23.75M | 95.99M |
Net Change In Cash | -42.81M | 23.27M | -21.01M | 61.94M | 449K | -7.23M | -22.65M | -25.84M | 25.30M | 33.12M |
Cash at end of period | 31.16M | 73.98M | 50.70M | 71.72M | 9.77M | 9.32M | 16.56M | 39.21M | 65.06M | 39.76M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |